Akoya Biosciences, Inc., (NASDAQ:AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a multi-site study to demonstrate and validate an automated end-to-end workflow that characterizes PD-1/PD-L1 immune checkpoint signaling in tumor tissue samples. The paper titled, “Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study),” was published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2021. The MITRE results are an important step toward standardizing an automated mIF-based spatial biology workflow that provides the level of performance needed to support clinical trials and that can be applied to clinical testing in the future.
Akoya Highlights Publication Of MITRE Study In The Journal For ImmunoTherapy Of Cancer
Akoya Biosciences, Inc., (NASDAQ:AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a multi-site study to demonstrate and validate an automated end-to-end workflow
Related Posts
If You Invested $1000 in Amazon Stock When It Acquired Whole Foods, Here’s How Much You’d Have Now
Ecommerce giant Amazon.com Inc (NASDAQ: AMZN) made its largest acquisition of all time in 2017 with the announcement it was purchasing physical retailer Whole Foods. Here’s a look at the acquisition and how shares have performed since the deal was announced.
Junshi Biosciences And Coherus Biosciences Announced Results Of A Final Analysis Of Overall Survival From Jupiter-02 Phase 3 Trial Of Toripalimab Plus Gemcitabine Plus Cisplatin As The First-line Treatment Recurrent Or Metastatic Nasopharyngeal Carcino…
This final analysis demonstrated a statistically significant and clinically meaningful improvement in overall survival in nasopharyngeal carcinoma patients treated with toripalimab plus chemotherapy compared to